Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in New Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 8 and 45 years~* Within 3 months of diagnosis of type 1 diabetes~* Have presence of at least one diabetes-related autoantibody~* Must have stimulated C-peptide levels of at least 0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) within one month of randomization~* If female with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing while participating in the study~* Have not received an immunization for at least one month~* Must be willing to comply with intensive diabetes management~* Must weigh at least 25 kg at study entry~Exclusion Criteria:~* Are immunodeficient or have clinically significant chronic lymphopenia~* Have an active infection or positive purified protein derivative (PPD) test result~* Currently pregnant or lactating; or anticipate becoming pregnant.~* Require chronic use of steroids~* Have current or past HIV, hepatitis B, or hepatitis C infection~* Have any complicating medical issues that interfere with study conduct or cause increased risk~* Have a history of malignancies~* Currently using non-insulin pharmaceuticals that effect glycemic control~* Currently participating in another type 1 diabetes treatment study

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab Intravenous Infusion (Type: EXPERIMENTAL): Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
- Placebo Intravenous Infusion (Type: PLACEBO_COMPARATOR): Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).